ReviewCurrent issues in molecular biology2025
Roxadustat as a Hypoxia-Mimetic Agent: Erythropoietic Mechanisms, Bioanalytical Detection, and Regulatory Considerations in Sports Medicine.
Review in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Evaluating antioxidant treatment approaches for eosinophilic chronic sinusitis.Frontiers in immunology · 2026Review
- Molecular Pharmacology at the Crossroads of Precision Medicine.Current issues in molecular biology · 2025Article
- Editorial for the Special Issue "Molecular Biology in Drug Design and Precision Therapy".Current issues in molecular biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Roxadustat (ROX) is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PHI) that exerts erythropoietic, cardioprotective, and metabolic regulatory effects. Approved for the treatment of anemia associated with chronic kidney disease, ROX promotes endogenous erythropoietin production and improves iron homeostasis, providing a non-injectable alternative to conventional erythropoiesis-stimulating agents (ESAs). Its ability to enhance oxygen transport and facilitate muscle recovery has, however, led to its misuse in sports, where it is classified as a banned substance by the World Anti-Doping Agency. This review provides a comprehensive overview of the pharmacological properties of ROX, its approved and investigational clinical applications, and its chemical synthesis strategies. Particular emphasis is placed on the analytical methodologies employed for ROX detection in anti-doping settings. Techniques such as liquid chromatography-tandem mass spectrometry (LC-MS/MS), ultraviolet-visible (UV-Vis) spectroscopy, Fourier-transform infrared spectroscopy (FT-IR), and high-performance thin-layer chromatography (HPTLC) are critically assessed for their efficacy in detecting ROX and its metabolites in biological matrices. Given the increasing incidence of ROX misuse among athletes, ongoing optimization of detection protocols and longitudinal monitoring approaches, are essential to uphold both sports integrity and public health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.